VYNE Therapeutics (VYNE)
(Delayed Data from NSDQ)
$1.99 USD
+0.09 (4.74%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $1.96 -0.03 (-1.51%) 7:58 PM ET
4-Sell of 5 4
F Value D Growth C Momentum F VGM
Income Statements
Fiscal Year end for VYNE Therapeutics Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 0 | 15 | 21 | 0 |
Cost Of Goods | 0 | 0 | 3 | 1 | 0 |
Gross Profit | 0 | 0 | 11 | 20 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 30 | 35 | 79 | 272 | 76 |
Income After Depreciation & Amortization | -29 | -34 | -68 | -253 | -76 |
Non-Operating Income | 1 | 0 | 0 | 1 | 3 |
Interest Expense | 0 | 0 | 6 | 4 | 0 |
Pretax Income | -28 | -34 | -74 | -256 | -74 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -28 | -34 | -73 | -256 | -74 |
Extras & Discontinued Operations | -1 | 11 | 0 | 0 | 0 |
Net Income (GAAP) | -28 | -23 | -73 | -256 | -74 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -30 | -34 | -68 | -198 | -76 |
Depreciation & Amortization (Cash Flow) | 0 | 0 | 0 | 55 | 0 |
Income After Depreciation & Amortization | -29 | -34 | -68 | -253 | -76 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 10.27 | 3.19 | 2.86 | 1.17 | 0.33 |
Diluted EPS Before Non-Recurring Items | -2.72 | -10.65 | -25.54 | -141.73 | -222.30 |
Diluted Net EPS (GAAP) | -2.78 | -7.28 | -25.54 | -141.73 | -222.30 |
Fiscal Year end for VYNE Therapeutics Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 0.20 | 0.10 | 0.08 | 0.11 | 0.14 |
Cost Of Goods | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 0.20 | 0.10 | 0.08 | 0.11 | 0.14 |
SG&A, R&D, and Dept/Amort Expenses | 10.60 | 7.48 | 6.91 | 6.35 | 10.45 |
Income After SG&A, R&D, and Dept/Amort Expenses | -10.40 | -7.38 | -6.83 | -6.24 | -10.31 |
Non-Operating Income | 1.00 | 1.14 | 0.68 | 0.16 | 0.28 |
Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | -9.40 | -6.24 | -6.15 | -6.07 | -10.04 |
Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -9.40 | -6.24 | -6.15 | -6.07 | -10.04 |
Extras & Discontinued Operations | -0.01 | -0.01 | -0.04 | -0.51 | -0.02 |
Net Income (GAAP) | -9.41 | -6.25 | -6.19 | -6.58 | -10.06 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 42.59 | 42.58 | 31.05 | 3.28 | 3.27 |
Diluted EPS Before Non-Recurring Items | -0.22 | -0.15 | -0.20 | -1.85 | -3.08 |
Diluted Net EPS (GAAP) | -0.22 | -0.15 | 4.06 | -2.01 | -3.09 |